Novo Nordisk submits proposal to acquire Metsera, Inc.

Core Viewpoint - Novo Nordisk has submitted an unsolicited proposal to acquire Metsera, Inc., aiming to enhance its portfolio in the obesity and diabetes treatment space [1][2]. Proposal Details - The acquisition proposal includes a cash offer of 56.50 USD per share, representing an approximate equity value of 6.5 billion USD and an enterprise value of about 6.0 billion USD. Additionally, contingent value rights (CVRs) could provide up to 21.25 USD per share based on clinical and regulatory milestones, amounting to a potential total of 2.5 billion USD [3]. - The cash consideration will be paid at signing for non-voting preferred stock representing 50% of Metsera's share capital, while the CVRs will be issued upon closing of the acquisition for the remaining shares [3]. Company Background - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, with a focus on chronic diseases, particularly diabetes. The company employs approximately 78,400 people across 80 countries and markets its products in around 170 countries [5].